Zydus receives final approval from USFDA for Budesonide Capsules

05 May 2017 Evaluate

Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Budesonide Capsules, 3 mg (Enteric Coated). The drug is a corticosteroid used for its anti-inflammatory action. 

Budesonide Capsules will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Budesonide is $285.8 million, as per IMS MAT March 2017. The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

893.45 11.50 (1.30%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×